Clinical Report: Shining a Light into the ADC Conjugation Black Box
Overview
Researchers at Genentech have developed a novel approach using ammonium tartrate in hydrophobic interaction chromatography (HIC) to enhance real-time monitoring of antibody-drug conjugates (ADCs). This method preserves separation performance while enabling compatibility with mass spectrometry, transforming HIC into a valuable tool for process analytical technology in ADC manufacturing.
Background
Antibody-drug conjugates (ADCs) represent a significant advancement in targeted cancer therapy, combining the specificity of antibodies with the potency of cytotoxic drugs. Accurate characterization of ADCs, particularly the drug-to-antibody ratio (DAR) and drug load distribution (DLD), is crucial for ensuring therapeutic efficacy and safety. Traditional methods for ADC characterization have limitations, necessitating innovative approaches to enhance process understanding and control.
Data Highlights
No numerical data or trial data available in the source material.
Key Findings
Rephrase findings for clarity and ensure they are directly supported by the source.Clinical Implications
The integration of ammonium tartrate in HIC provides a rapid and effective means for real-time monitoring of ADC production, potentially improving the quality control processes in bioconjugation. This advancement may lead to better therapeutic outcomes by ensuring consistent ADC quality during manufacturing.
Conclusion
Reiterate the significance of findings in ADC development and regulatory context.
References
- Genentech, Shining a Light into the ADC Conjugation Black Box, 2023 -- Article on HIC and ADCs
- Retinal Physician — Shedding Some Light on Current Endoillumination
- dana-farber — 2025 SABCS Highlights: Advances in ADC's for Advanced Breast Cancer
- Ophthalmology Management — Spotlight on Technology & Technique
- The New Path to ADCs
- 2025 SABCS Highlights: Advances in ADC's for Advanced Breast Cancer
- FDA approves fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HR-positive, HER2-low or HER2-ultralow breast cancer
- ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma - ScienceDirect
- Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis - ScienceDirect
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Newsletters
Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.
About the Author(s)
James Strachan
Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at. From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.
